Slovenian drug maker Krka's 2023 net profit declines 14%

Consolidated sales revenue increased by 5% to 1.806 billion euro in 2023, Krka said on Thursday in a statement on Wednesday.

The operating profit (EBIT) of the Krka group grew 5% on the year to 399.6 million euro, while the operating profit before depreciation and amortisation (EBITDA) went up 3% to 504.2 million euro.

The Krka group allocated 131.9 million euro to investments in 2023, of which 111.8 million euro placed by the controlling company.

The group employed 11,780 workers at the end of December, with 45% of them employed by the subsidiaries of Krka d.d. abroad.

Eastern Europe generated the highest sales within the group - of 593.9 million euro, down 5% on the year, with product sales in Russia - Krka's largest individual market, declining by 10%, to 346.8 million euro.

Sales in Central Europe rose 9% on the year to 397.1 million euro in 2023, followed by sales of 369.6 million euro in Western Europe, up by an annual 13%.

Sales in Southeast Europe grew 11% to 249.3 million euro in the period under review, whereas sales in Slovenia increased 10% to 113.8 million euro and sales in the Overseas Markets segment went up 14% to 75.2 million euro.

($ = 0.91385 euro)